Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-25T05:29:31.887Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment duration of obsessive compulsive disorder

Published online by Cambridge University Press:  16 April 2020

OT Dolberg ,
I Iancu  and
J Zohar
OT Dolberg
Affiliation:
Psychiatric Division, Sheba Medical Center, Ramat-Gan52621, Israel
I Iancu
Affiliation:
Psychiatric Division, Sheba Medical Center, Ramat-Gan52621, Israel
J Zohar*
Affiliation:
Psychiatric Division, Sheba Medical Center, Ramat-Gan52621, Israel
*
*Correspondence and reprints.
Get access

Summary

The first breakthrough in the treatment of obsessive-compulsive disorder (OCD) came in 1967, when Fernandez and Lopez-Ibor reported on the efficacy of clomipramine (CMI) in the treatment of 16 patients with OCD (Fernandez and Lopez-Ibor, 1967). However, controlled studies with CMI were not published until 1980 (Montgomery, 1980; Thoren et al, 1980), and only in the last 5 years have large well-controlled studies been published (Clomipramine Collaborative Study, 1991). Several studies demonstrated that among the tricyclics (TCA), only CMI is effective in OCD, while effective antidepressants with a noradrenergic profile, such as desipramine (DMI), appear to be totally ineffective (Zohar and Insel, 1987; Goodman et al, 1990; Leonard et al, 1989). This selective response to TCA with a serotonergic profile led to the formulation of the serotonergic hypothesis of OCD and to the development and use of other serotonergic agents in the treatment of this disorder. Several drugs, possessing a serotonergic profile are currently being studied worldwide, among them CMI, fluoxetine, fluvoxamine, sertraline, paroxetine and citalopram. Currently, as the knowledge regarding the pharmacological approach to OCD is only beginning to accumulate, very little is known regarding treatment duration in OCD. In this review we shall attempt to examine the existing data regarding treatment duration in OCD.

Keywords

obsessive compulsive disorderclomipramineserotonin reuptake inhibitors
Type
Original articles
Information
European Psychiatry , Volume 11 , Issue 8 , 1996 , pp. 403 - 406
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Chouinard, G. Sertraline in the treatment of obsessive compulsive disorder: Two double-blind, placebo-controlled studies Int Clin Psychopharmacol 1992 7 suppl 37–41CrossRefGoogle ScholarPubMed
Clomipramine collaborative study group Arch Gen Psychiatry 48 1991 730–738CrossRefGoogle Scholar
Fernandez, CELopez-Ibor, JJ. Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Adas Luso-Espanolas Neurologia Psiquiatria y Ciencias Afines 1967; 26: 119–147Google Scholar
Fontaine, RChouinard, G. Fluoxetine in the long-term maintenance treatment of obsessive-compulsive disorder. Psychiatr Ann 1989; 19: 88–9110.3928/0048-5713-19890201-09CrossRefGoogle Scholar
Frenkel, ARosenthal, JNezu, AWinston, A. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder. Mount Sinai J Med 1990; 57: 348–352Google ScholarPubMed
Goodman, WKPrice, LHDelgado, PLet al.Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990; 47: 577–585CrossRefGoogle ScholarPubMed
Greist, JJefferson, JWKobak, KAet al.A 1-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10: 57–65CrossRefGoogle ScholarPubMed
Leonard, HSwedo, SKoby, Eet al.Treatment of obsessive-compulsive disorder with clomipramine and desmethylimipramine in children and adolescents: A double-blind crossover comparison. Arch Gen Psychiatry 1989; 46: 1088–1092CrossRefGoogle ScholarPubMed
Leonard, HLSwedo, SELenane, MCet al.A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 922–927CrossRefGoogle ScholarPubMed
Leonard, HLSwedo, SELenane, MCet al.A 2-to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 1993; 50: 429–439CrossRefGoogle ScholarPubMed
Levine, RHoffman, JSKnepple, EDKenin, M. Long-term fluoxetine treatment of a large number of obsessive-compulsive patients. J Clin Psychiatry 1989; 9: 281–283Google ScholarPubMed
Mallya, GKWhite, KWaternaux, CQuay, S. Short-and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Ann Clin Psychiatry 1992; 4: 77–80CrossRefGoogle Scholar
Marks, IMStern, RSMawson, Det al.Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 1980; 136: 1–25CrossRefGoogle Scholar
Mawson, DMarks, IMRamm, L. Clomipramine exposure for chronic obsessive-compulsive rituals: III. Two year follow-up and further findings. Br J Psychiatry 1982; 140: 11–18CrossRefGoogle ScholarPubMed
Montgomery, SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmacologic Med 1980; 1: 89Google Scholar
Orloff, LMBattle, MABaer, Let al.Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 1994; 151: 441–442Google ScholarPubMed
O'Sullivan, GMarks, IMLong-term outcome of phobic and OCD after exposure: a reviewNoyes, R, et al.Handbook of Anxiety Amsterdam: Elsevier Press, 1990Google Scholar
Pato, MTZohar-Kadouch, RZohar, JMurphy, DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145: 1521–1522Google ScholarPubMed
Pato, MTHill, JLMurphy, DL. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. Psychopharmacol Bull 1990; 26: 211–214Google ScholarPubMed
Pollard, CAIbe, IOKrojanker, DNet al.Clomipramine treatment of trichotillomania. A follow-up report of four cases. J Clin Psychiatry 1991; 52: 128–130Google ScholarPubMed
Ravizza, LBarzega, GBellino, Set al.Predictors of response and long-term treatment of obsessive-compulsive disorder Darcourt, GMendlewicz, JRacagni, GBrunello, NCurrent Therapeutic Approaches to Panic and Other Anxiety Disorders Basel: Karger: International Academy of Biomedical Drug Research, 1994 164–170Google Scholar
Steiner, MBushnell, WDGergel, IWheadon, DE. Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine American Psychiatric Association Annual Meeting May 1995Google Scholar
Thoren, PAsberg, MGronholm, Bet al.Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980; 37: 1281–1285CrossRefGoogle ScholarPubMed
Zohar, JInsel, T. Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987; 22: 667–687CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.